Preparation of a therapeutic composition

Details Preparation of a therapeutic composition Preparation of a therapeutic composition

2009-04-27

2011-12-27

Davis, Ruth (Department: 1651)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using actinomycetales

C435S041000, C435S068100, C435S070100, C435S071100

Reexamination Certificate

active

08084239

ABSTRACT:
Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.

REFERENCES:
patent: 4448774 (1984-05-01), Clemente et al.
patent: 4743596 (1988-05-01), Lapin
patent: 4845215 (1989-07-01), Shimada et al.
patent: 5142056 (1992-08-01), Kempf et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5376642 (1994-12-01), Yarchoan et al.
patent: 5449608 (1995-09-01), Young et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5597824 (1997-01-01), Norbeck et al.
patent: 5670675 (1997-09-01), Kempf et al.
patent: 5783397 (1998-07-01), Hughes et al.
patent: 5807839 (1998-09-01), Hirschman
patent: 5807840 (1998-09-01), Hirschman
patent: 5849196 (1998-12-01), Kochel
patent: 5891742 (1999-04-01), Dollinger et al.
patent: 5902786 (1999-05-01), Bregman
patent: 5948231 (1999-09-01), Fuchs et al.
patent: 6071715 (2000-06-01), Qian et al.
patent: 6207861 (2001-03-01), Nash et al.
patent: 6268349 (2001-07-01), Hirschman
patent: 6303153 (2001-10-01), Friedland et al.
patent: 6312602 (2001-11-01), Kochel
patent: 6355226 (2002-03-01), Hirschman
patent: 6440658 (2002-08-01), Huang et al.
patent: 6528098 (2003-03-01), Friedland et al.
patent: 6670118 (2003-12-01), Hirschman
patent: 6696422 (2004-02-01), Hirschman
patent: 6921542 (2005-07-01), Friedland et al.
patent: 7067139 (2006-06-01), Hirschman
patent: 7074767 (2006-07-01), Friedland et al.
patent: 7179592 (2007-02-01), Dunayevskiy et al.
patent: 7439234 (2008-10-01), Hirschman
patent: 7465711 (2008-12-01), Hirschman
patent: 7524661 (2009-04-01), Friedland et al.
patent: 2001/0006682 (2001-07-01), Hirschman
patent: 2001/0007857 (2001-07-01), Hirschman
patent: 2001/0036920 (2001-11-01), Hirschman
patent: 2001/0049351 (2001-12-01), Hirschman
patent: 2002/0004579 (2002-01-01), Friedland et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0081627 (2002-06-01), Hirschman
patent: 2002/0107184 (2002-08-01), Hirschman
patent: 2003/0158107 (2003-08-01), Friedland et al.
patent: 2003/0206962 (2003-11-01), Hirschman
patent: 2004/0033244 (2004-02-01), Hirschman
patent: 2005/0180966 (2005-08-01), Hirschman
patent: 2007/0141044 (2007-06-01), Hirschman
patent: 2009/0305944 (2009-12-01), Hirschman
patent: 726830 (2000-11-01), None
patent: 2285463 (2005-06-01), None
patent: 2285573 (2008-09-01), None
patent: 0988042 (2000-03-01), None
patent: 147496 (2005-07-01), None
patent: 225306 (2005-01-01), None
patent: 98/46077 (1998-10-01), None
patent: 9846241 (1998-10-01), None
patent: 9846624 (1998-10-01), None
patent: 01/00306 (2001-01-01), None
patent: 01/32933 (2001-05-01), None
patent: 01/33188 (2001-05-01), None
patent: 02/20043 (2002-03-01), None
patent: 02/056833 (2002-07-01), None
patent: 2004/054581 (2004-01-01), None
patent: 2005/018661 (2005-03-01), None
patent: 2005/079269 (2005-09-01), None
patent: 2006/026604 (2006-03-01), None
patent: 2006/091222 (2006-08-01), None
patent: 2006/132623 (2006-12-01), None
Anderson, Robert H. and Thompson, Ralph M., Treatment of Viral Syndrome with a Lipoprotein-Nucleic Acid Compound (Reticulose), a Report of Five Cases, Virginia Medical Monthly, 84: 347-353, 1957.
Friedland, Bernard, In Vitro Antiviral Activity of a Peptide-Nucleic Acid Solution Against the Human Immonodeficiency Virus and Influenza A Virus, J. Roy. Soc. Health, Oct. 1991, 170-171.
Altman, M.D.,Lawrence, The Doctor's World; Troubling Side Effects are Linked to Effective Aids Drug Therapy, The New York Times (Apr. 7, 1998).
Schoofs, Mark, The Berlin Patient, The New Yor Times (Jun. 21, 1998).
Turjanica, Mary Ann, Aids: a Picture of Reality, Jannetti Publications, Inc. Medsurg Nursing (Aug. 1998).
Stull, Robert, A., and Szoka, Jr., Francis C.; Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects. Pharm. Res. (vol. 12 No. 4) 1995.
Ho and Parkinson, Antisense Oligonucleotides as Therapeutucs for Malignant Diseases; Seminars on Oncology, vol. 24 No. 2 Apr. 1997 pp. 187-202.
Hirschmann, Shalom Z. & Wei Chen, Chey; Peptide Nucleic Acids Stimulate Gamma Interferon and Inhibit the Replication og the Human Immunodeficiency Virus (J. Investig Med. 1996; 44; pp. 347-351.
Geleniunas, Arts, Boulerice, Goldman, Wainberg; Effect of 3′-Azido-3′-Dioxythymidine on Human Immunodeficiency Virus Type 1 Replication in Human Fetal Brain Microphages; Antimicrobial Agents & Chemotherapy, Jun. 1993, p. 1305-1312.
Dorsey, et al.; The design of a Potent and Orally Bioavailable HIC Protease Inhibitor,J. of Medicinal Chem. vol. 37 No. 21 (Oct. 14, 1994).
Danner, M.D., Sven A., et al. ;A Short-Term Study on the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease; NEJM, Dec. 7, 1995.
“Reticulose: Panar-097/ADVR-AR-97002 Repoert on Clinical and Laboratory assessments Obtained on HPV-Infected Volunteer Patients After 9 Months of Treatment”—May 1998.
Deborah A. Lazzarino, Maribel de Diego, Elgilda Musi, Shalom Z. Hirschman, Richard J. Alexander CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. Immunology Letters 74 (2000) 189-195, Jun. 27, 2000.
E.C Breen, A.R. Rezai, K. Nakajima, G.N. Beall, R.T Mitsuyasu, T. Hirano, T. Kishimoto & O. Martinez-Maza “Infection with HIV is associated with elevated IL-6 levels and production.” J. Immunol. 144:480-4 (1990)[90111057].
A.R. Rezai, A.R. Rezai, O. Martinez-Maza, M. Vander-Meyden & M.H. Weiss “Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors.” J. Neurooncol. 19: 131-135(1994)[95054302].
J.G. Norris, L.P. Tang, S.M. Sparacio & E.N. Benviste “Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha.” J. Immunol. 152:841-50(1994)[94110640].
Cecilia Graziosi, Giuseppe Pantaleo, Kira R. Gantt, Jean-Pierre Fortin, James F. Demarest, Oren J. Cohen, Rafick P. Sékaly, Anthony S. Fauci “Lack of Evidence for the Dichotomy of TH1 and TH2 Predominance in HIV-Infected Individuals.” Science vol. 265 pp. 248-252(Jul. 8, 1994).
Roberto Manetti, Maurizio Carbonari, Anna Maria Pesce, Gianfranco Del Prete, Sergio Romagnani “Ability of HIV to Promote a TH1 to TH0 Shift and to Replicate Preferentially in TH2 and TH0 Cells.” Science vol. 265 pp. 244-248(Jul. 8, 1994).
Edward Barker, Carl E. Mackewicz, & Jay A. Levy “Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival.” Proc. Natl. Acad. Sci. USA vol. 92, pp. 11135-11139, Nov. 1995 Immunology.
Thompson, Colonel Ralph M. USAF (MC); “A Lipo-Protein-Nucleic acid Complex in the Treatment of Radiation Injury (A Preliminary Report)”; The Military Surgeon vol. 110, No. 1 Jan. 1952.
Hirsch, Martin S. et al. “Effects of Interferon-Alpha on Cytomegalovirus Reactivation Syndromes in Renal Transplant Recipients”; The New England Journal of Medicine, vol. 308, No. 25, Jun. 23, 1983.
Egholm, Michael, et al. “Peptide Nucleic Acids(PNA).Oligonucleotide Analogues with an Archiral Peptide Backbone”; J. Am. Chem. Soc. 1992,114, 1895-1897.
Roffler, Chan and Yeh “Potentiation of Radioimmunotherapy by Inhibition of Topoisomerase I”; Cancer Research 54, 1276-1285, Mar. 1, 1994.
Kuckku, Morris E., Herpetic Diseases, Symposium, pp. 7-13, 1960.
Schaeffer, Oden A., Influenza Symposium, pp. 15-21, 1960.
Seydel, Frank, Epidemic, Asian Influenza, Symposium, pp. 23-24, 1960.
Cooke, Stanford B., Upper Respiratory Viral Manifestations, Clinical Symposium on Viral Diseases Demonstrating the Anti-viral Biotic Properties of the Drug Reticulos (Symposium), Se

Affiliated with

Also associated with

Rating

Preparation of a therapeutic composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation of a therapeutic composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of a therapeutic composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4259336